HB Wealth Management LLC bought a new position in Immunic, Inc. (NASDAQ:IMUX – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 78,400 shares of the company’s stock, valued at approximately $81,000.
Several other hedge funds also recently modified their holdings of the business. Jane Street Group LLC increased its holdings in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares during the last quarter. State Street Corp boosted its position in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Immunic in the third quarter valued at approximately $50,000. Institutional investors and hedge funds own 51.82% of the company’s stock.
Immunic Stock Up 2.8 %
Shares of NASDAQ IMUX opened at $1.02 on Friday. Immunic, Inc. has a 12-month low of $0.92 and a 12-month high of $2.11. The firm’s 50-day simple moving average is $1.10 and its 200 day simple moving average is $1.31. The company has a market cap of $91.88 million, a price-to-earnings ratio of -0.83 and a beta of 1.88.
Wall Street Analyst Weigh In
IMUX has been the topic of several recent analyst reports. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Immunic in a research report on Tuesday, January 7th. Finally, HC Wainwright assumed coverage on Immunic in a research report on Monday, November 25th. They set a “buy” rating and a $10.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $12.67.
Get Our Latest Report on Immunic
Insider Buying and Selling at Immunic
In related news, Director Richard Alan Rudick acquired 87,300 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was acquired at an average cost of $1.15 per share, with a total value of $100,395.00. Following the completion of the purchase, the director now directly owns 87,300 shares in the company, valued at approximately $100,395. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 3.00% of the company’s stock.
About Immunic
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Featured Articles
- Five stocks we like better than Immunic
- Ride Out The Recession With These Dividend Kings
- Bloom Energy: Powering the Future With Decentralized Energy
- What Do S&P 500 Stocks Tell Investors About the Market?
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- What is the Dow Jones Industrial Average (DJIA)?
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Want to see what other hedge funds are holding IMUX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunic, Inc. (NASDAQ:IMUX – Free Report).
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.